Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as ...

The Food and Drug Administration on Tuesday approved a once-monthly dose form of the cholesterol drug Praluent. The drug, co-developed by Regeneron Pharmaceuticals and Sanofi, first earned FDA ...

DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage of ...

PARIS, July 9 (Reuters) - French drugmaker Sanofi and U.S. partner Regeneron said the results of a late-stage study of their Praluent injection in Japan showed the drug reduced "bad cholesterol" among ...

Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent ® (alirocumab) - Praluent continues to be available to patients in the U.S. - Paris, ...